Avoro Capital Advisors LLC Purchases Shares of 1,800,000 GH Research PLC $GHRS

Avoro Capital Advisors LLC purchased a new stake in shares of GH Research PLC (NASDAQ:GHRS) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,800,000 shares of the company’s stock, valued at approximately $22,860,000.

Several other hedge funds and other institutional investors also recently modified their holdings of GHRS. Barclays PLC increased its position in shares of GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in GH Research during the fourth quarter valued at approximately $38,000. Osaic Holdings Inc. grew its stake in GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in GH Research in the 2nd quarter worth approximately $79,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of GH Research in the 4th quarter worth $128,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on GHRS. Needham & Company LLC raised their price objective on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a report on Friday, March 6th. HC Wainwright reduced their price target on shares of GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Tuesday, April 21st. Guggenheim set a $34.00 price objective on shares of GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Citigroup reaffirmed an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GH Research has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $22.24 on Friday. GH Research PLC has a 1 year low of $11.32 and a 1 year high of $25.94. The stock has a market capitalization of $1.53 billion, a P/E ratio of -24.17 and a beta of 1.31. The company’s 50-day moving average is $20.86 and its 200 day moving average is $16.93.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Research analysts anticipate that GH Research PLC will post -1.46 earnings per share for the current year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.